Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market
SAN DIEGO, June 30, 2025 /PRNewswire/ — Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful closing of its $18 million Series B financing. The round was led by Digitalis Ventures, with continued…